Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28606802 | 0.98 | EPHX2 (0.47) | EPHX2DGKAMAPTDNM1MEN1 | |
| SCHEMBL28377219 | 0.98 | EPHX2 (0.47) | EPHX2DGKAMAPTDNM1MEN1 | |
| Triethylene Glycol SCHEMBL29106630 | 0.95 | EPHX2 (0.45) | EPHX2DGKAMAPTDNM1MEN1 | |
| Di(Hydroxyethyl)Ether SCHEMBL28589497 | 0.94 | DGKA (0.44) | EPHX2DGKAMAPTDNM1MEN1 | |
| SCHEMBL29861229 | 0.93 | DGKA (0.55) | EPHX2DGKAMAPTDNM1ALDH1A1 | |
| SCHEMBL34109 | 0.93 | DGKA (0.55) | EPHX2DGKAMAPTDNM1ALDH1A1 | |
| SCHEMBL28835957 | 0.93 | DGKA (0.55) | EPHX2DGKAMAPTDNM1ALDH1A1 | |
| SCHEMBL769549 | 0.93 | DGKA (0.55) | EPHX2DGKAMAPTDNM1ALDH1A1 | |
| SCHEMBL6061688 | 0.93 | DGKA (0.55) | EPHX2DGKAMAPTDNM1ALDH1A1 | |
| SCHEMBL26474150 | 0.90 | DGKA (0.52) | EPHX2DGKAMAPTDNM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 734 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403085-B2 | Hair coloring with coconut oil | L'OREAL (FR) | 2025-09-02 | — | — | US | claimed |
| US-20250235435-A1 | INHIBITION OF CRYSTAL GROWTH OF ROFLUMILAST | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2025-07-24 | — | — | US | claimed |
| US-12336983-B2 | Inhibition of crystal growth of roflumilast | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2025-06-24 | — | — | US | claimed |
| CN-119564549-B | Avocado cleansing cream containing modified avocado oil additive | 上海正喧品牌管理有限公司 | 2025-05-16 | — | — | CN | claimed |
| US-20250127767-A1 | Roflumilast Formulations with an Improved Pharmacokinetic Profile | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | claimed |
| CN-119564549-A | Avocado cleansing cream containing modified avocado oil additive | 上海正喧品牌管理有限公司 | 2025-03-07 | — | — | CN | claimed |
| US-20250049771-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2025-02-13 | — | — | US | claimed |
| US-12220409-B2 | Roflumilast formulations with an improved pharmacokinetic profile | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2025-02-11 | — | — | US | claimed |
| US-20250000777-A1 | MONOPHASE MICELLAR COSMETIC CLEANSING COMPOSITION | L'OREAL (FR) | 2025-01-02 | — | — | US | claimed |
| CN-118986793-A | Plant sterol ester/oryzanol self-assembled gel and preparation method and application thereof | 杭州配方师科技有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-117297986-A | Cleaning cosmetic | 株式会社芳珂 | 2023-12-29 | — | — | CN | claimed |
| CN-117281742-A | Thermal skin-cleaning cleansing cream and preparation method thereof | 诺斯贝尔化妆品股份有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-117180142-A | Face-cleaning cleansing cream and preparation method thereof | 广东黛维依生物科技有限公司 | 2023-12-08 | — | — | CN | claimed |
| US-11793796-B2 | Inhibition of crystal growth of roflumilast | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | claimed |
| CN-114533590-B | Cleansing composition capable of suspending petal particles, preparation method and application thereof | 广州卡迪莲化妆品科技有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-115317387-B | Cleansing cream and preparation method thereof | 广州天然国度生物科技有限公司 | 2023-08-18 | — | — | CN | claimed |
| CN-111163748-B | Cosmetic composition comprising pigment and method for preparing the same | 株式会社爱茉莉太平洋 | 2023-04-21 | — | — | CN | claimed |
| US-11560497-B2 | Adhesive sheet | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-01-24 | — | — | US | claimed |
| CN-115317387-A | Makeup removing cream and preparation method thereof | 广州天然国度生物科技有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-114010538-A | Makeup removing cream and preparation method thereof | 诺斯贝尔化妆品股份有限公司 | 2022-02-08 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793796-B2 | Inhibition of crystal growth of roflumilast | PDE12, PDE4A, PDE5A | EPHX2 2989/4885DGKA 2356/4885MAPT 1067/4885 |
| US-20250127767-A1 | Roflumilast Formulations with an Improved Pharmacokinetic Profile | PDE12, PDE4A, PDE4C | EPHX2 984/4885DGKA 534/4885MAPT 1025/4885 |
| US-20250235435-A1 | INHIBITION OF CRYSTAL GROWTH OF ROFLUMILAST | PDE12, PDE4A, PDE5A | EPHX2 2921/4885DGKA 2368/4885MAPT 1014/4885 |
| US-20250000777-A1 | MONOPHASE MICELLAR COSMETIC CLEANSING COMPOSITION | PHOSPHO1, CHIT1, LIPA | EPHX2 2666/4885DGKA 270/4885MAPT 3497/4885 |
| US-12403085-B2 | Hair coloring with coconut oil | SHH, SMO, SPOP | EPHX2 2158/4885DGKA 2025/4885MAPT 3511/4885 |
| US-20250049771-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | PDE12, PDE4A, SMPD4 | EPHX2 1449/4885DGKA 771/4885MAPT 2681/4885 |
| US-12220409-B2 | Roflumilast formulations with an improved pharmacokinetic profile | PDE12, PDE4A, PDE4C | EPHX2 984/4885DGKA 534/4885MAPT 1025/4885 |
| US-12336983-B2 | Inhibition of crystal growth of roflumilast | PDE12, PDE4A, PDE5A | EPHX2 2921/4885DGKA 2368/4885MAPT 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.